Diversity-oriented synthetic strategy for developing a chemical modulator of protein-protein interaction

Nature Communications

Volumn 7, Issue , 2016, Pages

  Kim, Jonghoon ^a   Jung, Jinjoo ^a   Koo, Jaeyoung ^a   Cho, Wansang ^a   Lee, Won Seok ^a   Kim, Chanwoo ^a   Park, Wonwoo ^a   Park, Seung Bum ^a  

^a Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DIAZEPINE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INITIATION FACTOR 4E; LEUCINE TRANSFER RNA LIGASE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MOLECULAR SCAFFOLD; OXAZOLIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; MONOMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN BINDING; RRAGD PROTEIN, HUMAN;

AMINO ACID; BIOASSAY; BIOCHEMISTRY; CHEMICAL ANALYSIS; ENZYME; INHIBITOR; PROTEIN;

ARTICLE; AUTOLYSOSOME; AUTOPHAGY; BIOLOGICAL ACTIVITY; CATALYST; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; MOLECULAR LIBRARY; MOLECULE; NUCLEOPHILICITY; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTON NUCLEAR MAGNETIC RESONANCE; SIGNAL TRANSDUCTION; SYNTHESIS; CHEMICAL MODEL; CHEMISTRY; DRUG EFFECT; HEK293 CELL LINE; HELA CELL LINE; METABOLISM; PHARMACOLOGY; PROTEIN ANALYSIS; TUMOR CELL LINE;

CELL LINE, TUMOR; HEK293 CELLS; HELA CELLS; HUMANS; LEUCINE-TRNA LIGASE; MODELS, CHEMICAL; MOLECULAR STRUCTURE; MONOMERIC GTP-BINDING PROTEINS; PROTEIN BINDING; PROTEIN INTERACTION MAPS; PYRIMIDINES; SMALL MOLECULE LIBRARIES;

EID: 84992389086     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms13196     Document Type: Article

References (49)

1. Dandapani, S. & Marcaurelle, L. A. Grand challenge commentary: accessing new chemical space for 'undruggable' targets. Nat. Chem. Biol. 6, 861-863 (2010).
2. Swinney, D. C. & Anthony, J. How were new medicines discovered? Nat. Rev. Drug Discov. 10, 507-519 (2011).
3. O'Connor, C. J., Laraia, L. & Spring, D. R. Chemical genetics. Chem. Soc. Rev. 40, 4332-4345 (2011).
4. Schreiber, S. L. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 287, 1964-1969 (2000).
5. Schreiber, S. L. Organic chemistry: molecular diversity by design. Nature 457, 153-154 (2009).
6. Galloway, W. R. J. D., Isidro-Llobet, A. & Spring, D. R. Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules. Nat. Commun. 1, 80-86 (2010).
7. Kopp, F., Stratton, C. F., Akella, L. B. & Tan, D. S. A diversity-oriented synthesis approach to macrocycles via oxidative ring expansion. Nat. Chem. Biol. 8, 358-365 (2012).
8. Beckmann, H. S. et al. A strategy for the diversity-oriented synthesis of macrocyclic scaffolds using multidimensional coupling. Nat. Chem. 5, 861-867 (2013).
9. Huigens, R. W. III et al. A ring-distortion strategy to construct stereochemically complex and structurally diverse compounds from natural products. Nat. Chem. 5, 195-202 (2013).
10. Mizoguchi, H., Oikawa, H. & Oguri, H. Biogenetically inspired synthesis and skeletal diversification of indole alkaloids. Nat. Chem. 6, 57-64 (2014).
11. Zhang, J. et al. Diversity-oriented synthesis of Lycopodium alkaloids inspired by the hidden functional group pairing pattern. Nat. Commun. 5, 4614-4622 (2014).
12. Rizzo, S. & Waldmann, H. Development of a natural-product-derived chemical toolbox for modulation of protein function. Chem. Rev. 114, 4621-4639 (2014).
13. Ibbeson, B. M. et al. Diversity-oriented synthesis as a tool for identifying new modulators of mitosis. Nat. Commun. 5, 3155-3162 (2014).
14. Garcia-Carstro, M. et al. De novo branching cascades for structural and functional diversity in small molecules. Nat. Commun. 6, 6516-6528 (2015).
15. Oh, S. & Park, S. B. A design strategy for drug-like polyheterocycles with privileged substructures for discovery of specific small-molecule modulators. Chem. Commun. 47, 12754-12761 (2011).
16. Kim, H., Tung, T. T. & Park, S. B. Privileged substructure-based diversityoriented synthesis pathway for diverse pyrimidine-embedded polyheterocycles. Org. Lett. 15, 5814-5817 (2013).
17. Kim, J., Kim, H. & Park, S. B. Privileged structures: efficient chemical 'navigators' toward unexplored biologically relevant chemical spaces. J. Am. Chem. Soc. 136, 14629-14638 (2014).
18. Park, J., Oh, S. & Park, S. B. Discovery and target identification of an antiproliferative agent in live cells using fluorescence difference in two-dimensional gel electrophoresis. Angew Chem. Int. Ed. Engl. 51, 5447-5451 (2012).
19. Lee, S. et al. A small molecule binding HMGB1 and HMGB2 inhibits microgliamediated neuroinflammation. Nat. Chem. Biol. 10, 1055-1060 (2014).
20. Wakeling, A. E. et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 62, 5749-5754 (2002).
21. Wunder, F. et al. Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line. Mol. Pharmacol. 68, 1775-1781 (2005).
22. Yaziji, V. et al. Pyrimidine derivatives as potent and selective A3 adenosine receptor antagonists. J. Med. Chem. 54, 457-471 (2011).
23. Domling, A. Small molecular weight protein-protein interaction antagonists: an insurmountable challenge? Curr. Opin. Chem. Biol. 12, 281-291 (2008).
24. Crews, C. M. Targeting the undruggable proteome: the small molecules of my dreams. Chem. Biol. 17, 551-555 (2010).
25. Grivas, P. D., Kiaris, H. & Papavassiliou, A. G. Tackling transcription factors: challenges in antitumor therapy. Trends Mol. Med. 17, 537-538 (2011).
26. Vitaku, E., Smith, D. T. & Njardarson, J. T. Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals. J. Med. Chem. 57, 10257-10274 (2014).
27. Smith, S. G., Sanchez, R. & Zhou, M. M. Privileged diazepine compounds and their emergence as bromodomain inhibitors. Chem. Biol. 21, 573-583 (2014).
28. Han, J. M. et al. Leucyl-tRNA synthetase is an intracellular leucine sensor for the mTORC1-signaling pathway. Cell 149, 410-424 (2012).
29. Kim, I., Roh, S. W., Lee, D. G. & Lee, C. Rhodium-catalyzed oxygenative [2+2] cycloaddition of terminal alkynes and imines for the synthesis of b-lactams. Org. Lett. 16, 2482-2485 (2014).
30. Bailey, T. S., Bremner, J. B. & Carver, J. A. [2,3] Sigmatropic rearrangement of 1-vinylic tetrahydroisoguinoline N-Yileds and N-Oxides. Tetrahedron Lett. 34, 3331-3334 (1993).
31. 3-catalyzed diastereoselective ring opening of bridged oxazolidines: asymmetric synthesis of 2-azapodophyllotoxin. Chem. Eur. J. 17, 4905-4913 (2011).
32. Bremner, J. B. & Sengpracha, W. A free radical cyclization approach to indolo-benzodiazocine derivatives. Tetrahedron 61, 941-953 (2005).
33. Blanchard, N. & Eustache, J. in Metathesis in Natural Product Synthesis (eds Cossy, J., Arseniyadis, S. & Meyer, C.) 1-43 (Wiley-VCH, Weinheim, 2010).
34. Mak, J. Y. W., Pouwer, R. H. & Williams, C. M. Natural products with anti-Bredt and bridgehead double bonds. Angew Chem. Int. Ed. Engl. 53, 13664-13688 (2014).
35. Rosenblum, S. B. et al. Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption. J. Med. Chem. 41, 973-980 (1998).
36. Kinscherf, T. G. & Willis, D. K. The biosynthetic gene cluster for the beta-lactam antibiotic tabtoxin in Pseudomonas syringae. J. Antibiot. 58, 817-821 (2005).
37. Baumann, M. & Baxendale, I. R. An overview of the synthetic routes to the best selling drugs containing 6-membered heterocycles. Beilstein J. Org. Chem. 7, 442-495 (2011).
38. Bauer, R. A., Wenderski, T. A. & Tan, D. S. Biomimetic diversity-oriented synthesis of benzannulated medium rings via ring expansion. Nat. Chem. Biol. 9, 21-29 (2013).
39. Laplante, M. & Sabatini, D. M. mTOR signaling in growth control and disease. Cell 149, 274-293 (2012).
40. Efeyan, A., Comb, W. C. & Sabatini, D. M. Nutrient-sensing mechanisms and pathways. Nature 5179, 302-310 (2015).
41. Segev, N. & Hay, N. Hijacking leucyl-tRNA synthetase for amino acid-dependent regulation of TORC1. Mol. Cell 46, 4-6 (2012).
42. Cusack, S., Yaremchuk, A. & Tukalo, M. The 2A crystal structure of leucyl-tRNA synthetase and its complex with a leucyl-adenylate analogue. EMBO J. 19, 2351-2361 (2000).
43. Fingar, D. C. et al. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol. Cell Biol. 24, 200-216 (2004).
44. Kim, J., Kundu, M., Viollet, B. & Guan, K. L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 13, 132-141 (2011).
45. Pankiv, S. et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J. Biol. Chem. 282, 24131-24145 (2007).
46. Kondo, Y., Kanzawa, T., Sawaya, R. & Kondo, S. The role of autophagy in cancer development and response to therapy. Nat. Rev. Cancer 5, 726-734 (2005).
47. Rubinsztein, D. C., Gestwicki, J. E., Murphy, L. O. & Klionsky, D. J. Potential therapeutic applications of autophagy. Nat. Rev. Drug Discov. 6, 304-312 (2007).
48. Aldrich, L. N. et al. Discovery of a small-molecule probe for V-ATPase function. J. Am. Chem. Soc. 137, 5563-5568 (2015).
49. Gill, P. M. W., Johnson, B. G. & Pople, J. A. The performance of the Becke-Lee-Yang-Parr (B-LYP) density functional theory with various basis sets. Chem. Phys. Lett. 197, 499-505 (1992).